Arrhythmia and syncope are two important conditions that should be optimally managed. Many cases of recurrent atrial fibrillation do not lead to symptoms but still present a threat to the patient due to the risk of cerebral and systemic embolism, which not only applies to patients on drug therapy but also to those who have received catheter ablation. The detection of asymptomatic atrial fibrillation influences further treatment strategies, especially with regard to anticoagulation. Ensuring there is real-time access to data is an important consideration in identifying the best strategy to monitor atrial fibrillation and arrhythmias.

The goals of electrocardiographic (ECG) monitoring have expanded from simple heart rate and basic rhythm determination to the diagnosis of complex arrhythmias, detection of acute and often silent myocardial ischemia and identification of drug-induced prolonged QT interval. There is potential for event and continuous ECG monitoring to detect AF and arrhythmias in a timely manner, especially in a clinical trial setting,

Because clinical trials in cardiovascular medicine have grown in size, scope and complexity, the level of evidence required to support incremental new advances has increased substantially.

In this live webinar, our featured speaker will discuss trends in event and continuous ECG monitoring, and the implications for clinical trials of both medical device and therapies.

Keywords:

Speaker

Polina Voloshko, MD, Chief Medical Officer, BioTel Research

Dr. Polina Voloshko provides scientific and medical leadership, direction, training and expertise to the BioTelemetry clinical trial staff, cardiologists, medical and scientific consultants and sponsors. She has over 25 years of experience in clinical cardiology, ECG, ECHO and Holter research. Prior to joining the company, she was VP of Cardiovascular Clinical Services at the Ischemia Research and Education Foundation, Gentiae Clinical Research and Cardiocore. Previously, Dr. Voloshko served as a research fellow at the University of California San Francisco (UCSF) and Chief of Cardiology at Riga City Hospital in Riga, Latvia, an affiliate of the Latvian Medical University. Board-certified in cardiology and internal medicine, Dr. Voloshko received her MD, magna cum laude, at the First St. Petersburg Medical School in Russia.

Message Presenter

Who Should Attend?

This webinar will benefit medical and non-medical professionals in the biopharmaceutical industry, especially those supporting drug development with roles in:

Clinical Research
Clinical Development
Medical Affairs
Clinical Operations
Project Management
Regulatory Affairs

What You Will Learn

Attendees will learn:

Overview of Atrial Fibrillation and other arrhythmias
Principles of event and continuous ECG monitoring
Application of ECG monitoring in clinical trials

Xtalks Partner

BioTel Research

As an industry leader in testing services for clinical trials, BioTel Research combines the expert medical imaging of VirtualScopics and the cardiac core lab leadership of Cardiocore. BioTel Research offers global operational support for cardiovascular monitoring in all therapeutic areas, and advanced imaging services in oncology, cardiovascular, metabolic, musculoskeletal, neurologic and medical device studies. Their accessible and experienced research team comprises key opinion leaders, board-certified cardiologists and radiologists, sub-specialty scientists, and highly trained technicians — who acquire, evaluate, and report high-quality data through an efficient, cloud-based infrastructure. At BioTel Research, their job is to support your clinical trial with the most accessible and experienced team and the most advanced technologies available… through personal service on a global scale.